
Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD
Real-world study expands access to MDMA-assisted therapy for patients with PTSD and concurrent disor
Read More
Numinus builds on strong MAPS Phase 3 trial results through Compassionate Access Trial of MDMA for PTSD
[embed]https://youtu.be/sCIzz2rZGCI[/embed] Yesterday, MAPS announced significant, positive resul
Read More
Numinus Congratulates MAPS on Phase 3 Clinical Trial of MDMA for severe PTSD
[embed]https://www.youtube.com/watch?v=p2YxSIpuTks[/embed] 1 in 11 Canadians will suffer from PTS
Read More
Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD
Cliquez ici pour la version française Numinus and Multidisciplinary Association for Psychedelic
Read More
Numinus and MAPS to Collaborate on MDMA Trial for PTSD
Vancouver-based firm Numinus announced yesterday it will collaborate with an arm of a longstanding n
Read More
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial
First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support
Read More
Veterans Suffering from PTSD Find Relief Through Psilocybin
US Army Veteran Holly G. takes psilocybin to help make her combat-related PTSD more manageable. “K
Read More